Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...

Sage Therapeutics SAGE was in focus after it rejected Biogen's BIIB acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...

Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Sage Therapeutics SAGE announced that its board ... In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%. Earlier this month, Biogen made an acquisition ...

Sage Therapeutics has a unique approach to targeting ... This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime ...